Nicox: Bausch and Lomb entering phase III with latanoprostène bunod

BUY, Fair Value EUR3.7 vs. EUR3.2 (+12%)

News published on January Tuesday 29, 2013
Share on
NicOx and Bausch and Lomb (B+L) announced today the start of a phase III programme for latanoprostène bunod (ex NCX116 and BOL-303259-X). Two phase IIIs, APOLLO and LUNAR, will enroll 800 patients and compare intro ocular pressure (IOP) reduction and the safety profile of once-daily latanoprostène bunod versus twice daily Timolol. We believe that the study design looks favourable as the investigational compound will be compared with Timolol, a pretty old drug, whereas a study versus Xalatan (Pfizer), the active component of latanoprostène bunod, could have been more challenging.

Full report available to subscribers
Please contact

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities